Apr 26, 2018

Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).

In addition, the Company today announced that it will participate at the following upcoming investor conferences:

  • The 43rd Annual Deutsche Bank Securities Healthcare Conference on May 8, 2018 at 8:00 a.m. ET in Boston, MA;
  • The UBS Global Healthcare Conference on May 22, 2018 at 10:30 a.m. ET in New York, NY;
  • The Jefferies 2018 Global Healthcare Conference on June 6, 2018 at 2:00 p.m. ET in New York, NY; and
  • The JMP Securities Life Sciences Conference on June 20, 2018 at 9:30 a.m. ET in New York, NY.

A live webcast of the first quarter financial results and the investor presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the first quarter financial results webcast will be available on Concert’s website for three months. A replay of the investor conference webcasts will be available on Concert’s website for two weeks following the presentations.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

Source: Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals
Justine Koenigsberg, 781-674-5284
ir@concertpharma.com